Follow Us TR

News Details

89bio Initiates Phase 2 Trial of BIO89-100 in Patients with Severe Hypertriglyceridemia

About 89bio, Inc.
  • NASDAQ: $ETNB
  • Notified: $38.82
  • 08:31 EDT

Price Chart